Thus, it is crucial to improve the efficacy of EGFR‐TKIs against mutated tumor cells to prolong patient survival from the beginning of treatment, and selecting low‐toxicity, high‐efficiency drugs to alleviate resistance to EGFR‐TKIs during the treatment of lung cancer is a solution. This evidence concerns the gene EGFR and lung carcinoma.